Form 4: Amneal Pharmaceuticals Director Gautam Patel Acquires 40,258 Restricted Stock Units

Director Gautam Patel acquired 40,258 restricted stock units in Amneal Pharmaceuticals, Inc. on May 2, 2024.

Summary

• On May 2, 2024, Gautam Patel, a director of Amneal Pharmaceuticals, Inc., acquired 40,258 restricted stock units.
• Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• The restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
• Following the transaction, Patel directly owns 40,258 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units being granted. It doesn't inherently indicate positive or negative sentiment, but rather a routine part of executive compensation.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon future events, specifically the company's annual meeting of stockholders and the anniversary of the grant date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of restricted stock units, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of restricted stock units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates